Zentalis Pharmaceuticals Management
Management criteria checks 1/4
Zentalis Pharmaceuticals' CEO is Julie Eastland, appointed in Nov 2024, has a tenure of 1.08 years. total yearly compensation is $8.19M, comprised of 1.2% salary and 98.8% bonuses, including company stock and options. directly owns 0.039% of the company’s shares, worth $39.62K. The average tenure of the management team and the board of directors is 1 years and 3.3 years respectively.
Key information
Julie Eastland
Chief executive officer
US$8.2m
Total compensation
| CEO salary percentage | 1.15% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.04% |
| Management average tenure | 1yr |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval
Nov 18Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Aug 27
Is Zentalis Pharmaceuticals (NASDAQ:ZNTL) In A Good Position To Deliver On Growth Plans?
Aug 16We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully
Oct 03Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher
Jun 19We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jun 13Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit
May 09Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Apr 12We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Feb 29Zentalis: Leading WEE1 Developer After AstraZeneca's Exit
Feb 05Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?
Jan 09We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
Oct 13We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Jun 30We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Mar 17We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Dec 01Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer
Sep 27Zentalis Pharmaceuticals has a new chief medical officer
Sep 19Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
Aug 17Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
May 02We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jan 12We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Oct 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$149m |
| Jun 30 2025 | n/a | n/a | -US$163m |
| Mar 31 2025 | n/a | n/a | -US$224m |
| Dec 31 2024 | US$8m | US$94k | -US$166m |
Compensation vs Market: Julie's total compensation ($USD8.19M) is above average for companies of similar size in the US market ($USD577.34K).
Compensation vs Earnings: Insufficient data to compare Julie's compensation with company performance.
CEO
Julie Eastland (61 yo)
Ms. Julie M. Eastland, M.B.A., is Advisor of Trio Pharmaceuticals Inc. Ms. Julie M. Eastland is CEO, President & Director of Zentalis Pharmaceuticals, Inc. from November 12, 2024. Ms. Eastland joined the Z...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.1yrs | US$8.19m | 0.039% $ 39.6k | |
| SVP of Finance & Principal Accounting Officer | 1.7yrs | no data | 0.26% $ 263.9k | |
| Chief Legal Officer & Corporate Secretary | less than a year | no data | no data | |
| Chief People Officer | 1yr | no data | no data | |
| Senior Vice President of Technical Operations | less than a year | no data | no data | |
| Chief Medical Officer | 1.1yrs | no data | 0.028% $ 27.8k | |
| Chief Business Officer | 1yr | no data | no data | |
| Senior VP of Regulatory Affairs & Medical Writing | less than a year | no data | no data | |
| Senior VP & Head of Intellectual Property | less than a year | no data | no data |
Experienced Management: ZNTL's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.1yrs | US$8.19m | 0.039% $ 39.6k | |
| Chairman of the Board | 1.1yrs | US$1.03m | 0.029% $ 29.2k | |
| Independent Director | 3.3yrs | US$262.51k | 0.19% $ 190.9k | |
| Independent Director | 5.9yrs | US$321.42k | 0.27% $ 268.0k | |
| Independent Director | 1.6yrs | US$850.10k | 0.053% $ 53.3k | |
| Independent Director | 4.8yrs | US$262.51k | 0.11% $ 110.9k | |
| Independent Director | 8yrs | no data | no data |
Experienced Board: ZNTL's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/07 05:17 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zentalis Pharmaceuticals, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Andrew Fein | H.C. Wainwright & Co. |
| Andres Maldonado | H.C. Wainwright & Co. |